The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma
Authors:
- Laure ManeixLMLaure Maneix
- Melanie A. SweeneyMSMelanie A. Sweeney
- Sukyeong LeeSLSukyeong Lee
- Polina IakovaPIPolina Iakova
- Shannon E. MoreeSMShannon E. Moree
- Ergun SahinESErgun Sahin
- Premal LullaPLPremal Lulla
- Sarvari V. YellapragadaSYSarvari V. Yellapragada
- Francis T. F. TsaiFTFrancis T. F. Tsai
- Andre CaticACAndre Catic
Open Access
Abstract
Multiple myeloma and its precursor plasma cell dyscrasias affect 3% of the elderly population in the US. Proteasome inhibitors are an essential part of several standard drug combinations used to treat this incurable cancer. These drugs interfere with the main pathway of protein degradation and lead to the accumulation of damaged proteins inside cells. Despite promising initial responses, multiple myeloma cells eventually become drug resistant in most patients. The biology behind relapsed/refractory multiple myeloma is complex and poorly understood. Several studies provide evidence that in addition to the proteasome, mitochondrial proteases can also contribute to protein quality control outside of mitochondria. We therefore hypothesized that mitochondrial proteases might counterbalance protein degradation in cancer cells treated with proteasome inhibitors. Using clinical and experimental data, we found that overexpression of the mitochondrial matrix protease LonP1 (Lon Peptidase 1) reduces the efficacy of proteasome inhibitors. Some proteasome inhibitors partially crossinhibit LonP1. However, we show that the resistance effect of LonP1 also occurs when using drugs that do not block this protease, suggesting that LonP1 can compensate for loss of proteasome activity. These results indicate that targeting both the proteasome and mitochondrial proteases such as LonP1 could be beneficial for treatment of multiple myeloma.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK115454, T32DK60445)
- Cancer Prevention and Research Institute of Texas (RR140038)
- Welch Foundation (Q-1530-20190330)
This publication has 50 references indexed in Scilit:
- An investigation of the mechanisms underlying the proteasome inhibitor bortezomib resistance in PC3 prostate cancer cell lineCytotechnology, 2019
- Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignanciesBlood Cancer Journal, 2018
- Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyondLeukemia, 2017
- Proteasomal and Autophagic Degradation SystemsAnnual Review of Biochemistry, 2017
- Genomic complexity of multiple myeloma and its clinical implicationsNature Reviews Clinical Oncology, 2016
- Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolismLeukemia, 2016
- Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cellsInternational Journal of Cancer, 2013
- The resistance mechanisms of proteasome inhibitor bortezomibBiomarker Research, 2013
- Proteasome inhibitors in multiple myeloma: 10 years laterBlood, 2012
- Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cellsLeukemia, 2011